The Effect of Chemotherapy on Estradiol Levels in Patients with HER 2-Overexpression Breast Cancer in Dr Moewardi General Hospital, Surakarta, Indonesia
DOI:
https://doi.org/10.3889/oamjms.2021.6967Keywords:
Breast cancer, HER2 overexpression, Estradiol levels, Adjuvant chemotherapy, Developing countryAbstract
AIM: This study aims to evaluate the effect of adjuvant chemotherapy on estradiol levels in patients with HER 2-overexpression breast cancer in a developing country.
METHODS: This comparative study with pre- and post-design model observation approach, involving patients with HER 2-overexpression breast cancer who had undergone surgery and had never received chemotherapy or hormonal therapy before, who were then given adjuvant chemotherapy. Estradiol levels were measured before and after chemotherapy. The study was carried out in the surgical oncology division of RSUD Dr. Moewardi (RSDM) Surakarta from January 2020-December 2020. Descriptive data are presented in a frequency table based on age, menstrual status, parity status, breastfeeding status, contraception, contraception duration, family history, stage, and histological grade. Before and after chemotherapy in patients with breast cancer, the estradiol levels employed the paired sample t-test of the Wilcoxon rank test because the data did not meet the normality assumption.
RESULTS: From the total data of 21 patients, 15 patients experienced a decrease in estradiol levels after chemotherapy, while six patients underwent an increase. The mean estradiol level before chemotherapy was 89.41 pg/ml, whereas the mean estradiol level after chemotherapy was 55.90 pg/ml. It indicates a difference in the decrease in estradiol levels of 33.51 pg/ml. The statistical test results also obtained a p-value of = 0.033 (p < 0.05), which signifies a significant difference between estradiol levels before and after chemotherapy. Thus, chemotherapy is effective in lowering estradiol levels in patients with breast cancer.
CONCLUSION: Chemotherapy affects decreasing estradiol levels in patients with HER2 overexpression breast cancer.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Kimman M, Norman R, Jan S, Kingston D, Woodward M. The burden of cancer in member countries of the association of Southeast Asian nations (ASEAN). Asian Pac J Cancer Prev. 2012;13(2):411-20. https://doi.org/10.7314/apjcp.2012.13.2.411 PMid:22524799 DOI: https://doi.org/10.7314/APJCP.2012.13.2.411
McDonald M, Hertz RP, Lowenthal SW. The Burden of Cancer in Asia. PFIZER Medical Division; 2008.
Crandall CJ, Sehl ME, Crawford SL, Gold EB, Habel LA, Butler LM, et al. Sex steroid metabolism and mammographic density in pre-and early perimenopausal women. Breast Cancer Res. 2009;11(4):R51. https://doi.org/10.1186/bcr2340 PMid:19630952 DOI: https://doi.org/10.1186/bcr2340
Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Medicine, 2006;354(3):270-82. PMid:16421368 DOI: https://doi.org/10.1056/NEJMra050776
Yap KH, Tripathy D. A review of the management of T1a/bN0 HER2-overexpressed breast cancer. Am J Hematol Oncol. 2015;11:11-5.
Daniel R. Risk factors related to breast cancer development. Mastology. 2019;29(4):218-23. DOI: https://doi.org/10.29289/2594539420190000461
DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin. 2016;66(1):31-42. https://doi.org/10.3322/caac.21320 PMid:26513636 DOI: https://doi.org/10.3322/caac.21320
Hyun AH,Son BH, Kim SW, Kim SI, Jeong J, Ko SS. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: Nationwide survival data in Korea-a report from the korean breast cancer society. J Clin Oncol. 2007;25(17):2360-8. https://doi.org/10.1200/jco.2006.10.3754 PMid:17515570 DOI: https://doi.org/10.1200/JCO.2006.10.3754
Mojtaba S, Akrami M, Hmaidreza T. Breast cancer risk faktor in women participating in a breast screening program: A study on 11,850 Iranian females. Asian Pac J Cancer Prev. 2014;15(19):8499-502. https://doi.org/10.7314/apjcp.2014.15.19.8499 PMid:25339054 DOI: https://doi.org/10.7314/APJCP.2014.15.19.8499
Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: Individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012;13(11):1141-51. https://doi.org/10.1016/s1470-2045(12)70425-4 PMid:23084519 DOI: https://doi.org/10.1016/S1470-2045(12)70425-4
Sun Y, Zhao Z, Yang Z, Xu F, Lu HJ, Zhu ZY, et al. Risk factors and preventions of breast cancer. Int J Biol Sci. 2017;13(11):1387-97. PMid:29209143
Singletary SE. Rating the risk factors for breast cancer. Ann Surg. 2003;237(4):474-82. PMid:12677142 DOI: https://doi.org/10.1097/01.SLA.0000059969.64262.87
Tariq R, Saida H, Fatima A. Risk factors to hight prevalence of breast cancer. J Appl Pharm. 2014;1:706-12.
Islam F, Liu Y, Jemal A, Zhou J, Weiderpass E, Colditz G, et al. Breastfeeding and breast cancer risk by receptor status-a systematic review and meta-analysis. Ann Oncol. 2015;26(12):2398-407. https://doi.org/10.1093/annonc/mdv379 PMid:26504151 DOI: https://doi.org/10.1093/annonc/mdv379
Sun Y, Zhao Z, Yang Z, Xu F, Lu HJ, Zhu ZY, et al. Risk factors and preventions of breast cancer. Int J Biol Sci. 2017;13(11):1387-97. PMid:29209143 DOI: https://doi.org/10.7150/ijbs.21635
Alsammarrale AZ, Mubarak AA, Alnuaimi AS, Kamal AM. Association of oral contraceptives use with breast cancer and hormone receptor status in Iraqi women. Open Access Maced J Med Sci. 2020;8(B):1244-50. https://doi.org/10.3889/oamjms.2020.5030 DOI: https://doi.org/10.3889/oamjms.2020.5030
Brewer HR, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ. Family history and risk of breast cancer: An analysis accounting for family structure. Breast Cancer Res Treat. 2017;165(1):193-200. https://doi.org/10.1007/s10549-017-4325-2 PMid:28578505 DOI: https://doi.org/10.1007/s10549-017-4325-2
Kim JY, Han W, Moon HG, Ahn SK, Kim J, Lee JW, et al. Prognostic effect of preoperative serum estradiol level in postmenopausal breast cancer. BMC Cancer. 2013;13:503. https://doi.org/10.1186/1471-2407-13-503 PMid:24160328 DOI: https://doi.org/10.1186/1471-2407-13-503
Dang C, Hudis CA. Adjuvant Systemic Chemotherapy in Early Breast Cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK, editors. Diseases of the Breast. 5th ed., Ch. 44. Philadelphia, PA: Wolters Kluwer Health; 2014.
Mauri D, Gazouli I, Zarkavelis G, Papadaki A, Mavroeidis L, Gkoura S, et al. Chemotherapy associated ovarian failure. Front Endocrinol (Lausanne). 2020;11:572388. https://doi.org/10.3389/fendo.2020.572388 PMid:33363515 DOI: https://doi.org/10.3389/fendo.2020.572388
Passildas J, Collard O, Savoye AM, Dohou J, Ginzac A, Thivat E, et al. Impact of chemotherapy-induced menopause in women of childbearing age with non-metastatic breast cancer-preliminary results from the MENOCOR study. Clin Breast Cancer. 2019;19(1):e74-84. https://doi.org/10.1016/j.clbc.2018.10.003 PMid:30448088 DOI: https://doi.org/10.1016/j.clbc.2018.10.003
Huifen Z, Fan G, Jia M, Yarong Y. Anthraciclyn chemotherapy in treating advance breast cancer and effect on estradiol and tumor size. Indian J Pharm. 2020;82(1):20. DOI: https://doi.org/10.36468/pharmaceutical-sciences.spl.23
Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst. 2004;96(22):1659-68. https://doi.org/10.1093/jnci/djh312 PMid:15547178 DOI: https://doi.org/10.1093/jnci/djh312
Priyanka S, Sara LT, Jose AG, Claire W, Carol SC, Henry LG. Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: Combined analysis of two cohorts.Clin Cancer Res. 2017;23(3):649-57. PMid:27301700
Kolberg HC, Akpolat-Basci L, Stephanou M, Aktas B, Hannig CV, Liedtke C. Neoadjuvant chemotherapy with docetaxel, carboplatin and weekly trastuzumab is active in HER2-positive early breast cancer: Results after a median follow-up of over 4 years. Breast Care (Basel). 2016;11(5):323-7. http://doi.org/10.1159/000452079 PMid:27920624 DOI: https://doi.org/10.1159/000452079
Malisic E, Susnjar S, Milovanovic J, Todorovic-Rakovic N, Kesic V. Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia. Arch Gynecol Obstet. 2018;297(2):495-503. https://doi.org/10.1007/s00404-017-4581-8 PMid:29101609 DOI: https://doi.org/10.1007/s00404-017-4581-8
Braverman AS, Sawhney H, Tendler A, Patel N, Rao S, El-Tamer M, et al. Serum estradiol above the postmenopausal level after chemotherapy-induced amenorrhea in breast cancer patients. Clin Pract. 2006;3(5):609-12. http://doi.org/10.2217/14750708.3.5.609 DOI: https://doi.org/10.2217/14750708.3.5.609
Zhang N, Moran MS, Huo Q, Haffty BG, Yang Q. The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: A meta-analysis. Cancer Invest. 2011;29(9):594-8. https://doi.org/10.3109/07357907.2011.621913 PMid:22011281 DOI: https://doi.org/10.3109/07357907.2011.621913
Al-Saleh K, Saleh T, Arafah M, Husain S, Al-Rikabi A, El-Aziz NA. Prognostic significance of estrogen, progesterone and HER2 receptors’ status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia. PLoS One. 2020;16(3):e0247802. https://doi.org/10.1371/journal.pone.0247802 PMid:33667252 DOI: https://doi.org/10.1371/journal.pone.0247802
Manna S, Holz MK. Tamoxifen action in ER-negative breast cancer. Sign Transduct Insights. 2016;5:1-7. PMid:26989346 DOI: https://doi.org/10.4137/STI.S29901
Downloads
Published
How to Cite
License
Copyright (c) 2020 Imam Hafidh Zaini, Widyanti Soewoto, Ida Bagus Budhi (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
